Hims shares tumble as FDA chief warns of crackdown on illegal copycat weight loss drugs
Hims shares fell after the FDA chief warned of a crackdown on copycat drugs. The agency plans swift action against firms selling unapproved weight-loss medications.
Insights:
U.S. Food and Drug Administration Commissioner Marty Makary marty makary announced today, February 6, 2026, that the agency will take swift action against companies involved in the mass-marketing of illegal copycat drugs. This regulatory warning was issued shortly after the telehealth company Hims & Hers Health, Inc. began offering a lower-cost compounded version of Wegovy (Novo Nordisk weight-loss pill) produced by Novo Nordisk A/S .
